c-MYC partners with BPTF in human cancer

Laia Richart, Francisco X. Real, Víctor J. Sánchez‐Arévalo Lobo

Molecular & Cellular Oncology · 2016 · 29 citations · 7 references

DOIFull text

Open access

Concepts

Abstract

The c-MYC oncogene is deregulated in virtually all human tumors and therefore constitutes an attractive therapeutic target. We found that the chromatin remodeler BPTF is a c-MYC interactor required for c-MYC chromatin recruitment and transcriptional activity. Moreover, inhibition of BPTF delays tumor development both in vitro and in vivo and its levels positively correlate with c-MYC signatures in human tumors. We propose BPTF as a therapeutic target in c-MYC-addicted tumors.

References

7